{"contentid": 488303, "importid": NaN, "name": "Genmab and Seagen\u00e2\u0080\u0099s BLA for tisotumab vedotin accepted for priority review", "introduction": "The US Food and Drug Administration has accepted for Priority Review the Biologics License Application (BLA) seeking accelerated approval for tisotumab vedotin, that was submitted to the agency by Danish biotech firm Genmab and US firm Seagen.", "content": "<p>The US Food and Drug Administration has accepted for Priority Review the Biologics License Application (BLA) seeking accelerated approval for tisotumab vedotin, that was submitted to the agency by Danish biotech firm Genmab (OMX: GEN) and US firm Seagen (Nasdaq: SGEN) in February this year.</p>\n<p>This BLA requests FDA approval of tisotumab vedotin for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of October 10, 2021.</p>\n<p>The drug has been described as a &ldquo;Trojan horse&rdquo; because its ability to sneak inside cancer cells. Binding to tissue factor draws the drug inside cancer cells, where it can kill them from within.</p>\n<p>&ldquo;We are pleased that the tisotumab vedotin BLA has been accepted with Priority Review by the FDA as there is an unmet need for effective therapies for women with recurrent or metastatic cervical cancer, who have disease progression on or after chemotherapy,&rdquo; said Jan van de Winkel, chief executive of Genmab, adding: &ldquo;This is an important milestone for Genmab as it brings us closer to our goal of bringing differentiated therapies to patients and transforming cancer treatment.&rdquo;</p>\n<h2><strong>Clinical backing</strong></h2>\n<p>The FDA&rsquo;s filing of the tisotumab vedotin BLA with Priority Review marks an important step forward for this ADC as a potential treatment for patients with recurrent or metastatic cervical cancer,&rdquo; said Dr Roger Dansey, chief medical officer at Seagen. &ldquo;We are collaborating closely with the FDA throughout the review process to make this important therapy available to patients.&rdquo;</p>\n<p>The submission is based on the results of the innovaTV 204 pivotal Phase II single-arm clinical trial evaluating tisotumab vedotin as monotherapy in patients with previously treated recurrent or metastatic cervical cancer. These data were presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.</p>", "date": "2021-04-10 14:57:00", "meta_title": "Genmab and Seagen\u00e2\u0080\u0099s BLA for tisotumab vedotin accepted for priority re", "meta_keywords": "Genmab, Seagen, Tisotumab vedotin, BLA. Priority review, FDA, Cancer, Cervical", "meta_description": "Genmab and Seagen\u00e2\u0080\u0099s BLA for tisotumab vedotin accepted for priority review", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-10 14:55:28", "updated": "2021-04-10 15:09:39", "access": NaN, "url": "https://www.thepharmaletter.com/article/genmab-and-seagen-s-bla-for-tisotumab-vedotin-accepted-for-priority-review", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "seagen_large.jpg", "image2id": "seagen_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Oncology", "topic_tag": "Focus On, Regulation, US FDA", "geography_tag": "Denmark, USA", "company_tag": "Genmab, Seagen", "drug_tag": "tisotumab vedotin", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-10 14:57:00"}